Add BrightSurf on Google Email

Engineering a coating for disease-free produce

Researchers at Texas A&M University have developed a coating that bolsters the safety of fresh produce and provides enhanced protection against bacteria and fungi. The coating combines wax with nano-encapsulated cinnamon-bark essential oil in protein carriers to enhance antibacterial properties.

SourceTexas A&M University·JournalCurrent Research in Food Science·DateFeb 20, 2024

With regular exercise, medical weight loss treatment does not have to be permanent

A new study published in LANCET eClinicalMedicine found that regular exercise can help individuals maintain weight loss after completing medical weight loss treatment. The study showed that exercising just two hours a week can lead to better quality of life, improved mental health, and reduced fatigue.

Promising development for breast cancer patients

Researchers at Tohoku University have developed a novel monoclonal antibody targeting HER2-positive breast cancer cells, providing a new tool for treating this aggressive subtype. The antibody disrupts cell growth and proliferation while minimizing harm to surrounding healthy tissue.

SourceTohoku University·JournalInternational Journal of Molecular Sciences·DateFeb 19, 2024

Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas

Researchers at UCLA Health Jonsson Comprehensive Cancer Center have identified the protein TYRP1 as a promising target for CAR T-cell therapy. The study demonstrates potent antitumor responses against cutaneous and rare melanoma types, offering new hope for treating these challenging-to-treat cancers.

Fight against malaria takes a step forward

Scientists at the University of California, Riverside, have identified 898 RNA-dependent proteins in the deadliest human malaria parasite, Plasmodium falciparum. These findings could lead to novel therapeutic targets against malaria and highlight the importance of RNAs in biological pathways in the parasite.

SourceUniversity of California - Riverside·JournalNature Communications·TypeExperimental study·DateFeb 14, 2024

How T cells combat tuberculosis

Researchers at La Jolla Institute for Immunology have identified 137 unique T cell epitopes targeted by the immune system in patients with active TB. These findings may lead to the development of new diagnostics and therapies for the disease, which affects over 1.3 million people worldwide.

SourceLa Jolla Institute for Immunology·JournalNature Communications·TypeExperimental study·DateFeb 6, 2024

Researchers identify critical pathway responsible for melanoma drug resistance

In a new study, researchers have identified a specific epigenetic pathway involved in the development of therapy resistance in melanoma. The study found that targeting this pathway with a small molecule inhibitor called corin can successfully resensitize therapy-resistant cancers to targeted therapies.

SourceBoston University School of Medicine·JournalJournal of Clinical Investigation·TypeExperimental study·DateFeb 1, 2024

RNA sequencing analysis may hold the key to more accurate diagnosis and targeted treatment of pediatric B-acute lymphoblastic leukemia

A pilot study proposes a promising global genomic assay for diagnosing molecular subtypes in pediatric B-ALL, leading to more accurate diagnosis and targeted treatment options. RNA sequencing analysis accurately identified subtypes in all known cases and determined genetic subtype in 79% of previously unknown cases.

SourceElsevier·JournalJournal of Molecular Diagnostics·TypeExperimental study·DateJan 29, 2024

Breakthrough technology offers promising treatment for ischemic retinopathy

Researchers develop technology that alleviates retinal pathologies by targeting mitochondrial chaperone TRAP1, which is implicated in the breakdown of blood-retinal barrier and pathological neovascularization. This treatment approach holds great promise for revolutionizing the treatment landscape for ischemic retinopathy.

Progression of ALS linked to a membrane and an enzyme: mitochondria-endoplasmic reticulum disruption and loss of TBK1 activity

Researchers at Nagoya University have discovered a relationship between ALS progression and the disruption of mitochondria-associated membranes (MAM) and TBK1 activity. Decreased activation of TBK1 is linked to motor neuron death in ALS patients and mice with disrupted MAM.

SourceNagoya University·JournalProceedings of the National Academy of Sciences·DateJan 17, 2024

Molecular ‘super-glue’ shows promise of cancer drug discovery platform

Researchers at St. Jude Children's Research Hospital have developed a molecular glue that sticks to the cancer-related protein casein kinase 1 alpha (CK1α), leading to its destruction. The compound, SJ3149, displays broad anti-cancer activity and may have clinical utility as an alternative to conventional small molecule inhibitors.

SourceSt. Jude Children's Research Hospital·JournalNature Communications·DateJan 16, 2024

Sudden hearing loss: high-dose therapy does not lead to better outcomes than the standard treatment

A large-scale German-wide randomized controlled trial found that high-dose therapy with glucocorticoids is not more effective than standard treatment for sudden hearing loss. However, it was associated with a higher risk of side effects. Several hundred thousand people worldwide suffer from sudden hearing loss each year.

SourceMartin-Luther-Universität Halle-Wittenberg·JournalNEJM Evidence·TypeRandomized controlled/clinical trial·DateJan 4, 2024

Real world data shows impact of immunotherapy in populations underrepresented in clinical trials, according to JNCCN study

A recent study published in JNCCN found that patients from underrepresented groups treated with first-line immunotherapy for advanced Non-Small Cell Lung Cancer (NSCLC) showed similar survival outcomes as their White counterparts. The study analyzed data from 248 patients and highlighted the need for more diverse patient representation...

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateDec 11, 2023

Major breakthrough for severe asthma treatment

A landmark study found that 92% of patients with severe asthma can safely reduce inhaled steroid dose and more than 60% can stop all use, minimizing side effects like osteoporosis, diabetes, and cataracts. The SHAMAL study used biologic therapy benralizumab to control severe asthma without steroids.

SourceKing's College London·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateDec 8, 2023